Ionis Pharmaceuticals (IONS) Stock Forecast, Price & News

Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

Is Ionis Pharmaceuticals a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 3 sell ratings, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Ionis Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View analyst ratings for Ionis Pharmaceuticals or view top-rated stocks.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Ionis Pharmaceuticals.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings data on Wednesday, May, 4th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.68) by $0.22. The firm had revenue of $142 million for the quarter, compared to analysts' expectations of $122.46 million. Ionis Pharmaceuticals had a negative trailing twelve-month return on equity of 0.46% and a negative net margin of 0.36%. The business's revenue was up 26.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.64) earnings per share.
View Ionis Pharmaceuticals' earnings history.

What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?

Ionis Pharmaceuticals updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $612.37 million.

What price target have analysts set for IONS?

8 brokerages have issued 1-year price targets for Ionis Pharmaceuticals' shares. Their forecasts range from $26.00 to $65.00. On average, they expect Ionis Pharmaceuticals' share price to reach $41.88 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price.
View analysts' price targets for Ionis Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the following people:

• Dr. Brett P. Monia Ph.D., Founder, CEO & Director (Age 61, Pay $1.34M)
• Ms. Elizabeth L. Hougen, Exec. VP of Fin. & CFO (Age 60, Pay $862.13k)
• Mr. Patrick R. O'Neil Esq., Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 48, Pay $822.93k)
• Dr. Stanley T. Crooke, Scientific Advisor (Age 77, Pay $1.31M)
• Ms. B. Lynne Parshall Esq., J.D., Sr. Strategic Advisor & Director (Age 68, Pay $1.03M)
• Dr. Richard S. Geary, Exec. VP & Chief Devel. Officer (Age 64, Pay $868.91k)
• Ms. Onaiza Cadoret-Manier, Exec. VP and Chief Product Strategy & Operations Officer (Age 57)
• Mr. Joel Edwards, VP of Corp. Operations (Age 61)
• Mr. Darren Gonzales, Chief Accounting Officer & Sr. VP
• Dr. C. Frank Bennett, Exec. VP & Chief Scientific Officer (Age 65)

Who are some of Ionis Pharmaceuticals' key competitors?

Some companies that are related to Ionis Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Exact Sciences (EXAS), Repligen (RGEN), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO) and Exelixis (EXEL).
View all of IONS's competitors.

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.53%), Bellevue Group AG (6.99%), Clearbridge Investments LLC (4.57%), ARK Investment Management LLC (4.36%), Tweedy Browne Co LLC (2.06%) and First Trust Advisors LP (1.14%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends for Ionis Pharmaceuticals.

Which institutional investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Privium Fund Management B.V., Candriam Luxembourg S.C.A., Bellevue Group AG, Eversept Partners LP, Woodline Partners LP, International Biotechnology Trust PLC, and Altrinsic Global Advisors LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include Brett P Monia, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, and Spencer R Berthelsen.
View insider buying and selling activity for Ionis Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Ionis Pharmaceuticals stock?

IONS stock was acquired by a variety of institutional investors in the last quarter, including Tweedy Browne Co LLC, Clearbridge Investments LLC, Goldman Sachs Group Inc., Assenagon Asset Management S.A., Simplex Trading LLC, Vanguard Group Inc., Russell Investments Group Ltd., and TD Asset Management Inc..
View insider buying and selling activity for Ionis Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $37.63.

How much money does Ionis Pharmaceuticals make?

Ionis Pharmaceuticals has a market capitalization of $5.34 billion and generates $810 million in revenue each year. The company earns $-28.60 million in net income (profit) each year or ($0.200010) on an earnings per share basis.

How many employees does Ionis Pharmaceuticals have?

Ionis Pharmaceuticals employs 660 workers across the globe.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at (760) 931-9200, via email at [email protected], or via fax at 760-603-2700.